Marc Tessier-Lavigne - 21 May 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
21 May 2021
Net transactions value
-$2,811,048
Form type
4
Filing time
24 May 2021, 20:05:20 UTC
Next filing
04 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $2,282,468 -37,957 -1.5% $60.13 2,551,102 21 May 2021 Direct F1, F2, F3
transaction DNLI Common Stock Sale $528,580 -8,806 -0.35% $60.02 2,542,296 24 May 2021 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.67 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 3,253 restricted stock units.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.135 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.